Adience Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.45 M
- Company Age 17 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 18.82%
- Profit Growth 35.22%
- Ebitda 254.39%
- Net Worth 8.75%
- Total Assets 79.31%
About Adience Pharma
Adience Pharma Private Limited (APPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 27 February 2007 and has a history of 17 years and 11 months. Its registered office is in Delhi, India.
The Corporate was formerly known as Zlb Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.45 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Sawhney and Rishabh Sawhney serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24110DL2007PTC159817
-
Company No.
159817
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Feb 2007
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Adience Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Sawhney
|
Director | 27-Feb-2007 | Current |
|
Rishabh Sawhney
|
Director | 29-Aug-2023 | Current |
Financial Performance of Adience Pharma.
Adience Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 18.82% increase. The company also saw a substantial improvement in profitability, with a 35.22% increase in profit. The company's net worth moved up by a moderate rise of 8.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adience Pharma?
In 2019, Adience Pharma had a promoter holding of 22.22% and a public holding of 77.78%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Paviour Pharmaceuticals Private LimitedAnil Sawhney is a mutual person
-
Akriti Realcon Private LimitedAnil Sawhney is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Adience Pharma?
Unlock and access historical data on people associated with Adience Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adience Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adience Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
